About
About

We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
About Us

Leadership

Board of Directors

PCA Regenerative Medicine Advisory Board

Remyelination Advisory Board
Our Science
Our Science

Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivate progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
PCA Approach

Therapeutic Discovery Process

Publications
Pipeline & Programs
Pipeline & Programs

Naturally repairing or reversing damage caused by degenerative disease
Pipeline

Multiple Sclerosis Program

Strategic Partnerships
Investors & Media
Investors & Media
Overview

Corporate Governance

Press Releases

Events & Presentations

Stock Information

Analyst Coverage

SEC Filings

Annual Reports and Proxy Statements

Investor FAQ

Investor & Media Contacts

Event Details

B. Riley Securities’ Neuro & Ophthalmology Investor Conference

Apr 28, 2022 at 3:30 PM EDT

Click here for webcast